Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent

Bibliography

• PETITOU M, DUCHAUSSOY P, LEDERMAN I et al.: Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide 042 - deoxy-2-sulfamido-6-0-sulfo-alpha-D-glucopyranosyl) 1>4) 0 (beta-D-glucopyranosyluronic acid) (1>4) 0-(2-deoxy-2-sulfamido 3, 6 di 0 sulfo alpha-D-glucopyranosyl) (1 4) 0 (2 0 sulfo-alpha-L-idopyranosyluronic acid)-(1 4)-2-deoxy-2-sulfamido 6 0 sulfo D glucopyranose decasodium salt, a heparin fragment having high affinity for antithrombin III. Carbohydr: Res. (1986) 147:221–236.
   Google Scholar
• TORRI G, CASU B, GATTI G, PETITOU M, CHOAYJ, JACQUINET JC: Mono- and bidimensional 500 MHZ proton NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue. Biochem. Biophys. Res. Comm. (1985) 128:134–140.
   PubMed Web of Science ®Google Scholar
• PETITOU M, DUCHAUSSOY P, LEDERMAN I et al.: Synthesis of heparin fragments: A a-methyl alpha-pentaoside with high affinity for ATIII. Carbohydr: Res. (1987) 167:67–75.
   PubMed Web of Science ®Google Scholar
• WALENGA JM, JESKE WP, BARA L, SAMAMA MM, FAREED J: State-of-the-art article. Biochemical and pharmacologic rationale for the development of a heparin pentasaccharide. Thromb. Res. (1997) 86(1):1–36Review of the preclinical information ofpentasaccharide.
   Google Scholar
• HERBERT JM, PETITOU M, LORMEAU JC: SR90107A/0RG31540, a novel anti-Factor Xa antithrombotic agent. Cardiovasc. Drug Rev (1997) 15:1–26.
   Web of Science ®Google Scholar
• LORMEAU JC, HÈRAULT JP: The effect of the synthetic pentasaccharide SR 90107/ ORG 31540 on thrombin generation ex vivo is uniquely due to AT-mediated neutralization of Factor Xa. Thromb. Haemost (1995) 74(6):1474–1477.
   PubMed Web of Science ®Google Scholar
• ZITOUN D, BARA L, BLOCH ME SAMAMA MM: Plasma TFPI activity after intravenous injection of pentasaccharide and unfractionated heparin in rabbits. Thromb. Res. (1994) 75(5):577–580.
   PubMed Web of Science ®Google Scholar
• KAISER B, HOPPENSTEADT DA, JESKE W, WUN TC, FAREED J: Inhibitory effects of TFPI on thrombin and Factor Xa generation in vitro--modulatory action of glycosaminoglycans. Thromb. Res. (1994) 75(6):609–616.
   PubMed Web of Science ®Google Scholar
• WALENGA JM, FLORIAN M, HOPPENSTEADT DA et al.: Heparin, LMW heparins and HCII binding oligosaccharides, but not pentasaccharide, regulate TAFI. Thromb. Haemost. (2001) July Supp1:2011.
   Google Scholar
• GEROTZIAFAS GT, BARA L, BLOCH ME MAKRIS PE, SAMAMA MM: Treatment with LMWHs inhibits Factor VIIa generation during M vitro coagulation of whole blood. Thromb. Res. (1996) 81(4):491–496.
   PubMed Web of Science ®Google Scholar
• LORMEAU JC, HE.RAULT JP, HERBERT JM: Antithrombin mediated inhibition of Factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to AT. Thromb. Haemost. (1996) 76(1):5–8.
   PubMed Web of Science ®Google Scholar
• WIEBE E, O'BRIEN L, STAFFORD A, FREDENBURGH J, WEITZ J: Heparin catalysis of factor FIXa inhibition by antithrombin: Pentasaccharide-induced conformational change in antithrombin predominates over the template effect. Thromb. Haemost. (2001) July Suppl:P2101.
   Google Scholar
• TURPIE AGG, GALLUS AS, HOEK JA, FOR THE PENTASACCHARIDE INVESTIGATORS: A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl. J. Med (2001) 344:619–625.
   PubMed Web of Science ®Google Scholar
• ••Phase IIb clinical trial of fondaparinux (PENTATHLON).
   Google Scholar
• TURPIE G: The PENTATHLON 2000 study: Comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism after hip replacement surgery. Thromb. Haemost. (2001) July Supp1:0C48.
   Google Scholar
• LASSEN M: The EHPHESUS study: Comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin the prevention of venous thromboembolism after elective hip replacement surgery. Thromb. Haemost. (2001) July Supp1:0C45.
   Google Scholar
• ERIKSSON BI, BAUER KA, LASSEN MR, TURPIE AGG FOR THE STEERING COMMITTEE OF THE PENTASACCHARIDE IN HIP-FRACTURE SURGERY STUDY: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl. I Med (2001) 345:1298–304.
   PubMed Web of Science ®Google Scholar
• ••Phase III clinical trial of fondaparinux(PENTHIFRA).
   Google Scholar
• BAUER KA, ERIKSSON BI, LASSEN MR, TURPIE AGG FOR THE STEERING COMMITTEE OF THE PENTASACCHARIDE IN MAJOR KNEE SURGERY STUDY: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl. J. Med (2001) 345:1305–1310.
   PubMed Web of Science ®Google Scholar
• ••Phase III clinical trial of fondaparinux(PENTAMAKS).
   Google Scholar
• WALENGA JM, HOPPENSTEADT D, MAYUGA M, SAMAMA MM, FAREED J: Functionality of pentasaccharide depends on endogenous antithrombin levels. Blood (2000) 96(11):817a.
   Web of Science ®Google Scholar
• BONEU B, NECCIARI J, CARIOU R et al: Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ 0RG31540) with high affinity to antithrombin III in man. Thromb. Haemost (1995) 74(6):1468–1473.
   PubMed Web of Science ®Google Scholar
• WALENGA JM: Doctoral thesis: Factor Xa inhibition in mediating antithrombotic actions: application of a synthetic heparin pentasaccharide. Mention tres hien. Universite Pierre et Marie Curie, Paris VI, Paris, France (June 1987).
   Google Scholar
• JESKE W: Doctoral thesis: Pharmacologic studies on synthetic analogues of heparin with selective affinity to endogenous serine protease inhibitors. Loyola University Chicago, Chicago, IL, USA (May 1996).
   Google Scholar
• WALENGA JM, FAREED J, PETITOU M, SAMAMA M, LORMEAU JC, CHOAY J: Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model. Thromb. Res. (1986) 43:243–248.
   PubMed Web of Science ®Google Scholar
• WALENGAJM, PETITOU M, LORMEAU JC, SAMAMA M, FAREED J, CHOAY J: Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb. Res. (1987) 46:187–198.
   PubMed Web of Science ®Google Scholar
• WALENGA JM, BARA L, PETITOU M, SAMAMA M, FAREED J, CHOAY J: The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-Factor Xa activity. Thromb. Res. (1988) 51:23–33.
   PubMed Web of Science ®Google Scholar
• BEGUIN S, CHOAYJ, HEMKER HC: The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb. Haemost. (1989) 61(3):397–401.
   PubMed Web of Science ®Google Scholar
• WALENGA JM, KOZA MJ, LEWIS BE, PIFARRE. R: Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin. Appl. Thrombosis/flemostasis (1996) 2\(Suppl. 1):521–527.
   Google Scholar
• ELALAMY I, LECRUBIER C, POTEVIN F et al.: Absence of M vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of twenty-five patients with heparin associated thrombocytopenia. Thromb. Haemost. (1995) 74:1384–1385.
   PubMed Web of Science ®Google Scholar
• AHMAD S, JESKE WP, WALENGA JM et al.: Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin. Appl. Thrombosis/ Hemostasis (1999) 5(4):259–266.
   PubMed Web of Science ®Google Scholar
• PAOLUCCI F, CLAVIES M, DONAT F, NECCIARI J: In vitro protein binding of 0rg31540/5R90107A in human plasma and purified antithrombin III. Thromb. Haemost. (2001) July Suppl:P3095.
   Google Scholar
• HOBBELEN PMJ, VAN DINTHER TG, VOGEL GMT, VAN BOECKEL CAA, MOELKER HCT, MEULEMAN DG: Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb. Haemost. (1990) 63(2):265–270.
   PubMed Web of Science ®Google Scholar
• VOGEL GMT, MEULEMAN DG, BOURGONDIEN FGM, HOBBELEN PMJ: Comparison of two experimental thrombosis models in rats, effects of four glycosaminoglycans. Thromb. Res. (1989) 54:399–410.
   PubMed Web of Science ®Google Scholar
• CADROY Y, HANSON SR, HARKER LA: Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb. Haemost. (1993) 70(4):631–635.
   PubMed Web of Science ®Google Scholar
• VOGEL GMT, VAN AMSTERDAM RGM, KOP WJ, MEULEMAN DG: Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb. Haemost. (1993) 69(1):29–34.
   PubMed Web of Science ®Google Scholar
• TURPIE AGG, BAUER KA, ERIKSSON BI, LASSEN MR: Effect on efficacy and safety of the timing of the first pentasaccharide (fondaparinux, Arixtra) administration in the prevention of venous thromboembolism after major orthopedic surgery. Blood (2001) 98(11):1119.
   Google Scholar
• DAUD AN, AHSAN A, IQBAL 0 et al.: Synthetic heparin pentasaccharide depolymerization by heparinase I: Molecular and biological implications. Clio. Appl. Thromb. Haemost. (2001) 7(1):58–64.
   Google Scholar
• IQBAL 0, SHADID H, SILVER Pet al.: Heparinase is capable of neutralizing the anticoagulant and hemorrhagic effects of a synthetic pentasaccharide. Blood (2000) 96(11):52a.
   Google Scholar
• SHRIVER Z, SUNDARAM M, VENKATARAMAN G et al: Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. PNAS (2000) 97:10365–10370.
   PubMed Web of Science ®Google Scholar
• FAREED J, FU K, MA Q et al.: Bleeding effects of heparinomimetics can be antagonized by activated prothrombin complex concentrates and r-FVIIa in mono-therapeutic and combination regimens. Thromb. Haemost. (2001) July Suppl:P2635.
   Google Scholar
• WALENGA JM, FAREED J: Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide. Semin. Thromb. Hemost. (1985) 11(2):89–99.
   PubMed Web of Science ®Google Scholar
• BACHER P, FAREED J, HOPPENSTEADT D, WALENGA JM, IQBAL 0: Endogenous AT III as a limiting factor in the mediation of antiprotease actions of heparins and related oligosaccharides. Impact on the pharmacodynamic parameters as calculated by using functional methods. Thromb. Haemost. (1991) 65(6):932.
   Google Scholar
• CRE.PON B, DONAT F, BARZU T, HE.RAULT JP: Pharmacokinetic parameters of AT binding pentasaccharides in three animal species: Predictive value for humans. Thromb. Haemost. (1993) 69(6):654.
   Web of Science ®Google Scholar
• VAN AMSTERDAM RGM, VOGEL GMT, VISSER A, KOP WJ, BUITING MT, MEULEMAN DG: Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times. Arteriosc/er. DIFOR1/1. V3SC. Biol. (1995) 15(0495–503.
   PubMed Web of Science ®Google Scholar
• DONAT F, DURET JP, SANTONI A, CARIOU R, NECCIARI J, MAGNANI H, DEGREEF R: Pharmacokinetics of 0rg31540/5R90107A in young and elderly healthy subjects: A highly favourable pharmacokinetic profile. Thromb. Haemost. (2001) July Suppl:P3094.
   Google Scholar
• FAAJI RA, BURGGRAAF J, SCHOEMAKER HC, STIEKEMA J, SIEGERT C, COHEN AF: The influence of renal function on the pharmacokinetics and pharmacodynamics of 0RG31540/ 5R90107A. Thromb. Haemost. (1997) June Supp1:379.
   Google Scholar
• LAGRANGE F, VERGNES C, BRUN JL et al.: Absence of M vitro placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the human dually perfused cotyledon. Blood (2001) 98(11):1128.
   Google Scholar
• FAAJI RA, BURGGRAAF J, SCHOEMAKER RC, VAN AMSTERDAM RGM, COHEN AF: An interaction study with the pentasaccharide 0RG31540/ 5R90107A and oral piroxicam in healthy male volunteers. Thromb. Haemost. (2001) July Suppl:CD3569.
   Google Scholar
• FAAIJ RA, BURGGRAAF J, COHEN AF: Lack of pharmacokinetic and pharmacodynamic interaction between the first synthetic Factor Xa inhibitor and warfarin in human volunteers. Blood (2000) 96(11):5 6a.
   Google Scholar
• DONAT F, OLLIER C, SANTONI A, DUVAUCHELLE T: Safety and pharmacokinetics of co-administration of the first synthetic Factor Xa inhibitor and aspirin in human volunteers. Blood (2000) 96(11):5 4a.
   Google Scholar
• THE REMBRANDT INVESTIGATORS: Treatment of proximal deep vein thrombosis with a novel synthetic compound (5R90107A/0RG31540) with pure anti-Factor Xa activity. Circulation (2000) 102:2726–2731.
   PubMed Web of Science ®Google Scholar
• BERNAT A, HOFFMANN P, SAINTE-MARIE M, HERBERT JM: The synthetic pentasaccharide 5R90107A/Org 31540 enhances tissue-type plasminogen activator-induced thrombolysis in rabbits. Fibrino/ysis (1996) 10(3):151–157.
   Google Scholar
• KAISER B, FAREED J: Effect of unfractionated heparin and a heparin pentasaccharide on the thrombolytic process in an experimental model in rabbits. Fibrinolysis (1996) 1 0\(Suppl. 3):127.
   Google Scholar
• PISLARU SV, PISLARU C, ZHU X et al.: Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis. Thromb. Haemost. (1998) 79(6):1130–1135.
   PubMed Web of Science ®Google Scholar
• COUSSEMENT PK, BASSAND JP, COVENS C et al.: A synthetic Factor Xa inhibitor (0RG31540/5R90107A) as an adjunct to fibrinolysis in acute myocardial infarction. European Heart J. (2001) 22(18):1716–1724.
   PubMed Web of Science ®Google Scholar
• ••PENTALYSE clinical trial of fondaparinuxin acute coronary syndrome.
   Google Scholar
• VUILLEMENOT A, SCHIELE F, MENEVEAU N et al: Efficacy of a synthetic pentasaccharide, a pure Factor Xa inhibitor, as an antithrombotic agent-A pilot study in the setting of coronary angioplasty. Thromb. Haemost (1999) 81:214–220.
   PubMed Web of Science ®Google Scholar
• SIMOONS M: Oral presentation on the PENTUA clinical trial. 74th Annual Scientific Sessions of the American Heart Association, Anaheim CA, USA (November 14 2001).
   Google Scholar